STAT NewsOriginal article
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
Phase 3negativeNegative
AI Analysis
Summary
AstraZeneca is discontinuing a late-stage clinical trial for a drug candidate in metastatic non-small cell lung cancer patients, representing a setback for the company's pipeline.
Clinical Trial Data
Phase
late-stage
Primary Endpoint
Not Met
Outcome Details
late-stage drug trial discontinued
Importance:6/10
Sentiment:
-0.80
trial discontinuationlung cancersetbackclinical development
Related Companies
Read the original article
Published by STAT News on August 17, 2026 1:22 PM